148 related articles for article (PubMed ID: 20640586)
1. Factors influencing cardiovascular risk following termination of glucocorticoid therapy for nephrotic syndrome.
Nakamura A; Niimi R; Kurosaki K; Yanagawa Y
Clin Exp Nephrol; 2010 Oct; 14(5):457-62. PubMed ID: 20640586
[TBL] [Abstract][Full Text] [Related]
2. Body weight changes in children with idiopathic nephrotic syndrome.
Kuźma-Mroczkowska E; Pańczyk-Tomaszewska M; Skrzypczyk P; Artemiuk I; Roszkowska-Blaim M
Dev Period Med; 2016; 20(1):16-22. PubMed ID: 27416621
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for glucocorticoid-induced obesity in children with steroid-sensitive nephrotic syndrome.
Foster BJ; Shults J; Zemel BS; Leonard MB
Pediatr Nephrol; 2006 Jul; 21(7):973-80. PubMed ID: 16773410
[TBL] [Abstract][Full Text] [Related]
4. Interactions between growth and body composition in children treated with high-dose chronic glucocorticoids.
Foster BJ; Shults J; Zemel BS; Leonard MB
Am J Clin Nutr; 2004 Nov; 80(5):1334-41. PubMed ID: 15531684
[TBL] [Abstract][Full Text] [Related]
5. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome.
Leonard MB; Feldman HI; Shults J; Zemel BS; Foster BJ; Stallings VA
N Engl J Med; 2004 Aug; 351(9):868-75. PubMed ID: 15329424
[TBL] [Abstract][Full Text] [Related]
6. Changes in body mass index in long-term survivors of childhood acute lymphoblastic leukemia treated without cranial radiation and with reduced glucocorticoid therapy.
Touyz LM; Cohen J; Neville KA; Wakefield CE; Garnett SP; Mallitt KA; Grech AM; Cohn RJ
Pediatr Blood Cancer; 2017 Apr; 64(4):. PubMed ID: 27862918
[TBL] [Abstract][Full Text] [Related]
7. Expression of P-glycoprotein in lymphocytes of children with nephrotic syndrome treated with glucocorticoids.
Wasilewska AM; Zoch-Zwierz WM; Pietruczuk M
Eur J Pediatr; 2006 Dec; 165(12):839-44. PubMed ID: 16738866
[TBL] [Abstract][Full Text] [Related]
8. Sixteen-week versus standard eight-week prednisolone therapy for childhood nephrotic syndrome: the PREDNOS RCT.
Webb NJ; Woolley RL; Lambe T; Frew E; Brettell EA; Barsoum EN; Trompeter RS; Cummins C; Wheatley K; Ives NJ
Health Technol Assess; 2019 May; 23(26):1-108. PubMed ID: 31156083
[TBL] [Abstract][Full Text] [Related]
9. Genotypes of the renin-angiotensin system and glucocorticoid complications.
Nakamura A
Pediatr Int; 2015; 57(1):72-8. PubMed ID: 24980618
[TBL] [Abstract][Full Text] [Related]
10. Corticosteroid therapy for nephrotic syndrome in children.
Hodson EM; Knight JF; Willis NS; Craig JC
Cochrane Database Syst Rev; 2003; (1):CD001533. PubMed ID: 12535410
[TBL] [Abstract][Full Text] [Related]
11. Corticosteroid therapy for nephrotic syndrome in children.
Hodson EM; Knight JF; Willis NS; Craig JC
Cochrane Database Syst Rev; 2004; (2):CD001533. PubMed ID: 15106158
[TBL] [Abstract][Full Text] [Related]
12. Genetic and in vivo determinants of glucocorticoid sensitivity in relation to clinical outcome of childhood nephrotic syndrome.
Teeninga N; Kist-van Holthe JE; van den Akker EL; Kersten MC; Boersma E; Krabbe HG; Knoers NV; van der Heijden AJ; Koper JW; Nauta J
Kidney Int; 2014 Jun; 85(6):1444-53. PubMed ID: 24429396
[TBL] [Abstract][Full Text] [Related]
13. Corticosteroid therapy for nephrotic syndrome in children.
Hodson EM; Knight JF; Willis NS; Craig JC
Cochrane Database Syst Rev; 2001; (2):CD001533. PubMed ID: 11405997
[TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics of glucocorticoid-induced eye adverse reactions in children with primary nephrotic syndrome].
Zhao Y; Su BG; Xiao HJ; Zhang HW; Liu XY; Wang F; Ding J
Beijing Da Xue Xue Bao Yi Xue Ban; 2017 Oct; 49(5):794-797. PubMed ID: 29045958
[TBL] [Abstract][Full Text] [Related]
15. Three-monthly bolus vitamin D supplements (1000 vs 400 IU/day) for prevention of bone loss in children with difficult-to-treat nephrotic syndrome: a randomised clinical trial.
Singh DN; Krishnamurthy S; Kamalanathan SK; Harichandrakumar KT; Sivamurukan P
Paediatr Int Child Health; 2018 Nov; 38(4):251-260. PubMed ID: 30092157
[TBL] [Abstract][Full Text] [Related]
16. Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood.
Coleman JE; Watson AR
Pediatr Nephrol; 1996 Apr; 10(2):171-4. PubMed ID: 8703704
[TBL] [Abstract][Full Text] [Related]
17. Association of low birth weight and prematurity with clinical outcomes of childhood nephrotic syndrome: a prospective cohort study.
Konstantelos N; Banh T; Patel V; Vasilevska-Ristovska J; Borges K; Hussain-Shamsy N; Noone D; Hebert D; Radhakrishnan S; Licht CPB; Langlois V; Pearl RJ; Parekh RS
Pediatr Nephrol; 2019 Sep; 34(9):1599-1605. PubMed ID: 30976899
[TBL] [Abstract][Full Text] [Related]
18. Obesity among children and adolescents with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Völkl TM; Simm D; Beier C; Dörr HG
Pediatrics; 2006 Jan; 117(1):e98-105. PubMed ID: 16396852
[TBL] [Abstract][Full Text] [Related]
19. Corticosteroid therapy for nephrotic syndrome in children.
Hodson EM; Knight JF; Willis NS; Craig JC
Cochrane Database Syst Rev; 2000; (4):CD001533. PubMed ID: 11034723
[TBL] [Abstract][Full Text] [Related]
20. Ocular findings in Japanese children with nephrotic syndrome receiving prolonged corticosteroid therapy.
Hayasaka Y; Hayasaka S; Matsukura H
Ophthalmologica; 2006; 220(3):181-5. PubMed ID: 16679793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
